To help biopharmaceutical companies navigate the complexities of the Asia market, Quintiles today launched two unique services that will help increase the probability of success in developing and commercializing new medications in the region.
Quintiles new Strategic Drug Development organization was designated specifically to help BioPharma companies design and implement drug development strategies that take into account the Asia product commercialization opportunity and regulatory hurdles in advance of the standardized development process.
"Our goal is not only to help our customers meet their needs in the region, but also to help define them," said Amar Kureishi, Vice President and Chief Medical Officer for Quintiles in Asia. "Although we are only now launching the formal service, our world-class team has already worked with our customers on more than 15 projects to transform their development aspirations to a reality."
Also launched today is Quintiles Consulting practice in Asia, led by Christian Gabel, Ph.D., Vice President and Head of Consulting at Quintiles Asia.
The consulting group will help customers navigate the New Health by linking business strategy, industry expertise and data-driven insights within six practice areas to deliver transformational change.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Quintiles will be exhibiting at BioPharma Asia Convention 2012. Pre-register to visit the exhibition today.